| human | Q5 |
| P496 | ORCID iD | 0000-0002-3887-899X |
| P69 | educated at | University of Melbourne | Q319078 |
| P108 | employer | WEHI | Q7966487 |
| Denali Therapeutics (United States) | Q50037774 | ||
| P106 | occupation | researcher | Q1650915 |
| Q59332844 | Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis |
| Q39744193 | CIS is a potent checkpoint in NK cell-mediated tumor immunity |
| Q91095526 | Enzymatic Characterization of Wild-Type and Mutant Janus Kinase 1 |
| Q51713635 | JAK1 Takes a FERM Hold of Type II Cytokine Receptors. |
| Q33857008 | Mechanistic insights into activation and SOCS3-mediated inhibition of myeloproliferative neoplasm-associated JAK2 mutants from biochemical and structural analyses |
| Q92979635 | Negative regulation of RAF kinase activity by ATP is overcome by 14-3-3-induced dimerization |
| Q51188615 | Purification of SOCS (Suppressor of Cytokine Signaling) SH2 Domains for Structural and Functional Studies. |
| Q27676669 | SOCS3 binds specific receptor–JAK complexes to control cytokine signaling by direct kinase inhibition |
| Q54115189 | The molecular basis of JAK/STAT inhibition by SOCS1. |
Search more.